Sahm Adrangi Is Taking The Short Side With Proteostasis With Latest Negative Report From Kerrisdale

Sahm Adrangi is a well-known man in the investing world thanks to his many accomplishments as an investor and his success at Kerrisdale Capital. This private investment firm invests in various companies around the world. Today, being able to identify quality companies in the stock market is a challenge, and Sahm Adrangi is standing out where not many can. Kerrisdale has managed to excel and come out on top of the S&P 500 for several successive quarters.

On a normal basis, Kerrisdale Capital puts out reports on various companies in the market, and their latest was quite the negative report against biotech firm Proteostasis. This biotech company is home to Cambridge and has recently been making claims of a new breakthrough in terms of cystic fibrosis. Their new drug in development, PTI-428, is aimed at helping increasing lung performance in patients.

Unfortunately for Proteostasis, Kerrisdale was not impressed with their figures and the data they released, so Sahm Adrangi decided to do a little more digging into the company. Upon even closer examination of the results of the company, their actual test sample was extremely small. So small in fact, PTI-428 was only tested on four patients. This is not nearly enough to make such claims the company has been making, causing their company stock value to go up.

Kerrisdale took quickly to their report to get it out as soon as possible to inform the public and many investors out there of what is really behind this biotech company, Proteostasis. According to Sahm Adrangi, their drug cocktail is most likely an ineffective drug that works better as a placebo. Unfortunately for Proteostasis, the majority of their company value is invested in their product, which means they will lose more than 70% of their company share value when it comes out that PTI-428 is not effective.

As more companies and investors are becoming aware of the nature of this biotech company, their share values continue to drop and will likely push the company off the map in the near future.

http://www.imdb.com/name/nm1444924/

April 19, 2018

Posted In: Business, Business success, Businessman, CEO, Entrepreneur, Investor

Tags: , , , , , , , , ,

How OSI Group Became a Top 100 Company in the United States

The OSI Group always works hard to give their clients what they need. This is uncommon in food companies and it shows they’re dedicated to all the people they work with. It also shows they are among the best in the industry. Since they know they can do things right, they plan to always give people back the things that will make their business better. For the OSI Group, things have always been better than what they are for other companies. As long as the OSI Group can keep helping people, they feel good about their business. They know success of OSI Group will continue coming their way.

Even when things get difficult for the OSI Group, they know how to push forward. They’ve spent a long time learning about the different options they have and that’s how they plan to keep doing things for others. Even though other companies may not know what they need to do to see the same success as the OSI Group, they can try things on their own. They’ve spent a long time making sure people understand how things will work and how things will change depending on the area they’re in.

While the OSI Group is making news on an international level, they’re still working hard to make sure people know home matters too. They are among the top 100 in the United States. Since they are so dedicated to giving people the chances they need for success, they can keep growing. The growth allows them to produce more. When the company produces more, they give people a chance to try different things. They make a point of showing them how everything will get better and how their business will grow as a result of all the hard work they put into it.

For the OSI Group, the point is making sure they can do things to help others. They spend a lot of time giving everyone the options they need. It is how they work to help businesses. Whether the OSI Group gives small businesses help or large businesses help, they treat them the same way. The OSI Group believes small restaurants need the same kind of attention as big corporations. If they can provide people with this help, they know they’ll make all the right choices. They try to give everyone a chance at bringing attention to the issues on their own without problems in the industry.

Learn More: www.indeed.com/cmp/Osi-Group

April 17, 2018

Posted In: Business, OSI Group

Tags:

What’s Next For Dr. Clay Siegall & Seattle Genetics

Fighting cancer is no easy task. Producing good medications that fights cancer surely isn’t easy as well, but there organizations out there that are willing to put in the time and effort. Seattle Genetics just so happens to be one of those organizations, and it has made an extremely huge impact on this industry. Seattle Genetics was co-founded by Dr. Clay Siegall back in the late 1990s. Dr. Siegall may be one of the most accomplished and well-celebrated professionals in the game. He has a heart of gold as well as a brilliant mind. When it comes to fighting cancer, this dynamic duo has outperformed other duos and here is why.

Antibody-drug conjugates have reshaped cancer research for the better. These advanced drugs are superior, especially when being compared to the predecessors of the past. Dr. Siegall has implemented strong, core principles into this advanced program, and these principles have produced a successful company. Seattle Genetics has a pipeline full of medications, and four out of the 20 medications has great potential to hit the market in future years. ADCETRIS, the company’s top drug, has earned well-over $300 million in a rather short period of time. ADCETRIS is now being used all around the world thanks to Dr. Siegall. By participating in strategic-licensing deals, ADCETRIS has been distributed to the public by many drug companies like Pfizer, Genentech and GlaxoSmithKlien. The company’s growth-trajectory has drastically increased by 46 percent since 2014. In 2016, the company’s sales reached up to $400 million.

Dr. Siegall’s influence on this company can’t be denied, and it can’t be questioned. He is the oil that keeps this engine running, and he is the glue that holds everything together. Seattle Genetics and Dr. Clay Siegall are looking to take this company to the next level via research, innovation and drug development.

April 11, 2018

Posted In: Drug Development

Tempus Technologies of Eric Lefkofky Receives $ 80 Million

The name Eric Lefkofsky is trending because of some noble actions of the great inventor and technology geek. Eric is the CEO of Tempus; a technology outfit that has hit the news for months about its efforts to battle cancer by using cutting-edge technologies. He is also a co-founder of the company and a couple of others in the technology field. Eric is so conspicuous because of his liking for disruptive technologies that help enhance service delivery, especially in the health services sector. Eric also co-founded a NASDAQ-listed company by the name Groupon. The list of the tech companies Eric has helped to start or started on his own is long, but one of the most outstanding because of the contribution it has already made in the fight against cancer is Tempus. It is an operating system that uses personalized patient data to develop profiles and analysis of a patient’s cancer status and trends. Physicians have found the technology handy because it helps them make fast decisions about the cancer patients that they interact with; decisions that are often helpful in battling cancer before the condition spread its ominous tentacles too far. Tempus has already networked with many cancer centers in the US. Now it is getting some money for growth.

Tempus Receives More Donor Funding

According to reports by the Chicago Tribune recently, Mr. Eric Lefkofsky’s Tempus Company has just received a cash boost. It will be yet another gesture of support for the work by the young American inventor and technology enthusiast who uses his passion and skills in technology to promoter cancer treatment and handling. Tempus is noted to be an important resource in promoting upcoming technologies that prove to have the potential to change the old order of things, especially in the medical world. According to the Chicago Tribune report, Tempus has received over $ 80 million from what the news source describes as existing and new investors. So far, Tempus, under the umbrella of Groupon has received up to $210 million since it was started in 2015. Tempus breaks the record of companies that have had the most profound impact on humanity barely two years since they were started. The latest funding is a boost to Mr. Eric Lefkofky’s work in battling the cancer menace through technology. To know more about him click here.

His Contributions to Society

Eric Lefkofsky has demonstrated a heart for helping those who have been afflicted by disease and pain. He and his wife formed the Lefkofsky Family Foundation. The Foundation seeks to extend charity assistance to needy communities and individuals around the globe to resolve or mitigate their health concerns. Eric is a respected personality already. He is a trustee of Lurie Children’s Hospital based in Chicago, the Museum of Science among others.

April 3, 2018

Posted In: Businessman, CEO

Tags: